ProductsPricingFree Market DashboardMarket News FeedScannerChartsHeatmapMarket SectorsTrack RecordMAD AcademyMCP Connector

Denali Therapeutics Inc. (DNLI)

Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)

$18.68-0.25 (-1.32%)

As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.

Follow DNLI in real time

Real-time quotes, Pro Charting, the scanner and the alert feed on DNLI and every other US listing.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Or open the free DNLI chart →

DNLI at a glance

Key statistics

$3.03B

Market capitalization

Previous close
$18.93
Open
$18.93
Day range
$18.58 – $19.13
Volume
1.43M
Average volume (30 sessions)
1.91M
Shares outstanding
159.85M
Earnings per share
$(3.21)
Price / book
3.6
Price / sales
839.6
Beta (1 year, vs SPY)
1.56

Where the price sits in its year

52-week range

36% of the range

Below the 52-week high
-31.6%
Above the 52-week low
+35.9%

Completed sessions through Oct 21, 2026

Technical snapshot

Below its 50-day and 200-day averages

20-day average
$19.36-3.5%
50-day average
$21.47-13.0%
200-day average
$21.19-11.8%
RSI (14)41.8

Between the conventional 30 and 70 bands.

+4.5%

1 week

-13.5%

1 month

-20.2%

3 months

+13.1%

Year to date

+8.3%

1 year

Price change over each window, from completed sessions. Past performance does not indicate future results.

Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.

The member platform, in real time

What members do with DNLI

Every plan

DNLI on Pro Charting

Every intraday interval in real time, the drawing kit and the full set of technical studies on DNLI.

See the plans →

Every plan

Screen names like DNLI

The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.

See the plans →

Analysis Tools Only

Set a price line on DNLI

Put DNLI on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.

See the plans →

Stock Alerts + Tools

Open alerts on DNLI

See whether there is an open premium alert on DNLI, with its entry, stop and exit, each one reviewed by an analyst before it is sent.

See the plans →

From the public news wire

DNLI headlines

Market news →

SEC Form 4, most recent first

Insider filings

How to read these →

  • Chin Peter Scott

    −1.7K

    Chief Medical Officer · Open-market sale

    $36.87K · Sep 4, 2026

  • Thornberry Nancy

    −615

    Director · Open-market sale

    $14.60K · Sep 2, 2026

  • Thornberry Nancy

    −10.8K

    Director · Open-market sale

    $247.33K · Sep 2, 2026

  • Schuth Alexander O.

    −2.8K

    COFO and Secretary · Open-market sale

    $64.88K · Sep 1, 2026

  • Watts Ryan J.

    −32.2K

    President and CEO, Director · Gift

    · Aug 12, 2026

  • Schuth Alexander O.

    −2.9K

    COFO and Secretary · Open-market sale

    $71.62K · Aug 11, 2026

  • Cook Jennifer E.

    +6.4K

    Director · Grant or award

    · Jun 3, 2026

  • 667, L.P.

    +6.4K

    Director · Grant or award

    · Jun 3, 2026

About Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Exchange
Nasdaq
Security
Common stock
Industry
Biological Products, (no Diagnostic Substances)
Headquarters
South San Francisco, CA
Employees
507
Listed since
Dec 8, 2017
Website
denalitherapeutics.com
Educational content only. MadStockAlerts provides market commentary, research, and educational content. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security. Trading and investing involve substantial risk, including loss of capital. See the Risk Disclosure and Customer Agreement.

Pick the desk that fits how you trade

Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.